Aligning with the C-Suite! ESMO 2025 Unveils the Trend of ADC Oncology ‘Power Grab’
Author｜YY 01 Focus on the ADC signals The discussion at the 2025 European Society for Medical Oncology (ESMO) annual meeting once again centered on antibody-drug conjugates (ADCs). After over a decade of clinical accumulation, ADCs are gradually moving from treatment for metastatic and advanced tumors into earlier stages of disease. At this year’s conference, AstraZeneca … Read more